On this page
“Discussed by an FDA committee” does not mean “FDA approved.”
In July 2026, an FDA advisory committee considered several peptide-related bulk drug substances nominated for compounding. Separately, the FDA maintains a safety-risk table identifying concerns for multiple peptides. These processes evaluate compounding questions; they do not create approved indications.
| Substance | FDA concern highlighted | Evidence gap |
|---|---|---|
| BPC-157 | Immunogenicity, peptide impurities, API characterisation | Limited safety information for proposed routes |
| TB-500 fragment | Aggregation, impurities, immunogenicity | No identified human exposure data in drug products |
| MOTS-c | Immunogenicity, impurities, characterisation | No identified human exposure data in drug products |
| CJC-1295 | Immunogenicity and reported serious adverse events | Limited clinical data |
| Ipamorelin | Aggregation, impurities, unnatural amino acids | Insufficient safety information for several routes |
| GHK-Cu injectable | Aggregation, impurities, immunogenicity | Limited human safety data |
| Melanotan II | Published serious adverse-event case reports | No established assurance for marketed products |
| Semax / Selank | Aggregation, impurities, immunogenicity | Limited safety information |
What is the 503A Bulks List process?
Section 503A of US law creates a framework for certain traditional pharmacy compounding. A bulk substance nomination can be evaluated for possible inclusion. Nomination, committee discussion and a positive vote are procedural events—not proof that a finished product is approved, effective or appropriate for unsupervised use.
The four recurring scientific risks
Why one HPLC percentage is not enough
A chromatographic peak-area result does not by itself establish molecular identity, potency, sterility, endotoxin status or absence of all impurities. Orthogonal methods and a documented sampling chain are needed to answer different quality questions. This is especially important when a marketed name may refer to multiple chemical forms.
What the July 2026 meeting covered
The first day covered BPC-157, KPV, TB-500 and MOTS-c-related bulk substances. The second day covered emideltide or DSIP, Semax and Epitalon. FDA materials identify the proposed uses it evaluated, but those nominated uses should not be restated as accepted claims.
How Australian readers should interpret a US FDA page
FDA compounding policy governs the United States. It can still provide useful safety reasoning, but Australian scheduling, ARTG status, importation and advertising rules must be checked separately through the TGA. Regulatory conclusions are jurisdiction-specific.
Common questions
Does an FDA advisory-committee vote approve a peptide?
No. Advisory recommendations are part of a process. Approval of a finished therapeutic product requires a separate regulatory pathway.
Does compounding remove the need for clinical evidence?
No. Compounding policy and evidence of safety and effectiveness are different questions.
Why can injectable peptides be especially complex?
Sterility, endotoxin control, aggregation, formulation, impurities and immune responses all require controls beyond naming the active ingredient.
Primary sources
- FDA: bulk drug substances that may present significant safety risks
- FDA: July 2026 Pharmacy Compounding Advisory Committee
How to cite this article
FDA Peptide Compounding Safety Review (2026): BPC-157, TB-500, MOTS-c, CJC-1295 and More. Elite Peps Australia. Published 15 September 2026; updated 15 September 2026. https://elitepepsaustralia.com/fda-peptide-compounding-safety-review-2026/
Source checks: Consult the primary studies, trial records and regulator documents linked in this article for current evidence and status. Publication and update dates do not by themselves indicate an evidence review.